Andrea Wang-Gillam, MD, PhD

Andrea Wang-Gillam, MD, PhD

Associate Professor

Address:
Division of Oncology
Mail Stop 8056-0029-11
Washington University
660 South Euclid Avenue
St. Louis, MO 63110

11th Floor Mid Campus Center (office)

Research Interests
  • Pancreatic cancer
Research

I am a medical oncologist and scientist focusing on clinical and translational research in pancreatic cancer. My research passion is fueled by the fact that pancreatic cancer patients have a very low life expectancy due to lack of early detection and effective treatments. One of my research interests is to translate preclinical discoveries into clinical settings by designing and conducting hypothesis-driven trials. I am the principal investigator (PI) of several investigator-initiated clinical trials (see below) that were developed based on the promising preclinical discoveries made by my collaborators and colleagues. Moreover, my laboratory has been investigating the therapeutic potentials of various downstream effectors of KRAS, the key genetic oncogenic driver for pancreatic ductal adenocarcinoma.

  1. A phase I trial of defactinib plus pembrolizumab and gemcitabine in patients with refractory advance cancers (NCT02546531)
  2. A phase I trial of ERK inhibitor (BVD-523) plus nab-paclitaxel and gemcitabine in metastatic pancreatic cancer (NTC02608229)
  3. A phase I/II trial of tosedostat with capecitabine in patients with metastatic pancreatic adenocarcinoma (NTC02352831)
  4. A phase I trial of MLN8237 with nab-paclitaxel in patients with advanced solid malignancies (NTC01677559)
Profiles (publications)

Biosketch

Education

  • 2001-1995: MD, PhD, University of Arkansas College of Medicine, Little Rock, AR
  • 1993-1990: BS in Biology and Chemistry, Ouachita Baptist University, Arkadelphia, AR

Post-Graduate Training

  • 2007-2004: Fellow, Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR
  • 2004-2002: Resident, Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR
  • 2002-2001: Intern, Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH

Academic Positions

  • present-2015: Associate Professor, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
  • present-2015: Clinical Director, Gastrointestinal Oncology Program, Division of Oncology, Washington University School of Medicine, St. Louis, MO
  • 2020-2017: Director, Developmental Therapeutics Program, Division of Oncology, Washington University School of Medicine, St. Louis, MO
  • 2015-2007: Assistant Professor, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO

University & Hospital Committees

  • present-2017: Siteman Cancer Center Drug Developmental Program Focus Group Leader
  • present-2017: Siteman Cancer Center Senior Leadership Clinical Research Subcommittee
  • present-2014: Committee Member, Protocol Review and Monitoring Committee
  • present-2013: Siteman Cancer Center Upper GI Focus Group Leader
  • 2010-2007: Committee Member, Protocol Review and Monitoring Committee, Siteman Cancer Center

Board Certification

  • 2017, 2007: Medical Oncology
  • 2004: Internal Medicine

Honors & Awards

  • 2018-2015: Best Doctors in America List
  • 2012-2011: Siteman Cancer Center Protocol Specific Research Support Award
  • 2009-2008: Siteman Cancer Research Development Award
  • 2001-1996: MD-PhD Scholarship, University of Arkansas for Medical Sciences

National Committees

  • present-2018: Committee Member, Pancreatic Cancer Task Force, Gastrointestinal Cancer Steering Committee of National Cancer Institute
  • present-2017: Committee Member, Investigational Drug Steering Committee of NIH
  • present-2011: Committee Member, GI Committee, Alliance for Clinical Trials in Oncology
  • 2012-2010: Committee Member, Scientific Program Committee, American Society of Clinical Oncology
  • 2011-2010: Junior Investigator, National Cancer Institute Pancreatic Cancer Task Force
  • 2011-2007: Committee Member, Medical Oncology Committee, American College of Surgeons Oncology Group

Scientific Grant Review

  • 2025-2019: NIH Developmental Therapeutic Study Section
  • 2018: NIH Study Section
  • 2018, 2017, 2015: Cancer Research UK
  • 2017, 2015, 2013: Peer Reviewer, Cancer Research Program for the Department of Defense Congressionally Directed Medical Research Program
  • 2016: Florida Department of Health Review
  • 2016: Pennsylvania Department of Health Review

Professional Societies & Organizations

  • present-2013: Member, American Association for Cancer Research
  • present-2008: Member, American Pancreatic Cancer Association
  • present-2004: Member, American Society of Clinical Oncology